PROGNOSTIC VALUE OF pSTAT3 EXPRESSION IN DIFFUSIVE B-LARGE CELL LYMPHOMA IN THE RUSSIAN PATIENT SAMPLE
https://doi.org/10.15372/SSMJ20190515
Abstract
The aim of the study was to evaluate the prognostic value of pSTAT3 expression in diffuse B-large cell lymphoma (DLBCL) in a Russian sample of patients. Material and methods. Retrospectively, the results of an examination of 50 patients with newly diagnosed DLBCL in the period from 2014 to 2017 were evaluated. Using immunohistochemical and morphometric methods, the relative number of tumor cells expressing pSTAT3 was determined. The relationship of various levels of marker expression with clinical and laboratory parameters was analyzed, and long-term results of patient therapy were evaluated. Results and discussion. The overexpression of pSTAT3 protein is associated with a non-GCB subtype of the disease, an advanced stage, the patients of 60 years and older age, as well as with a lower frequency of achieving complete remissions with DLBCL. Patients with a high degree of marker expression in tumor cells had lower rates of overall (OS) and progressive survival (PFS). It was revealed that the marker under study has good predictive ability, but is not an independent prognosis factor for DLBCL. Conclusions. The level of expression of pSTAT3 is an informative factor that allows predicting the response to standard therapy for diffuse B-large cell lymphoma. The indicated marker may be useful for identifying patients who need individualization of therapeutic tactics for this disease.
About the Authors
E. V. Vaneeva
Kirov Research Institute of Hematology and Blood Transfusion of FMBA of Russia
Russian Federation
6100027, Kirov, Krasnoarmeyskaya str., 72
Russian Federation
6100027, Kirov, Krasnoarmeyskaya str., 72
V. A. Rosin
Kirov Research Institute of Hematology and Blood Transfusion of FMBA of Russia
Russian Federation
Russian Federation
candidate of medical sciences
6100027, Kirov, Krasnoarmeyskaya str., 72
D. A. Dyakonov
Kirov Research Institute of Hematology and Blood Transfusion of FMBA of Russia
Russian Federation
Russian Federation
candidate of medical sciences
6100027, Kirov, Krasnoarmeyskaya str., 72
S. V. Samarina
Kirov Research Institute of Hematology and Blood Transfusion of FMBA of Russia
Russian Federation
6100027, Kirov, Krasnoarmeyskaya str., 72
Russian Federation
6100027, Kirov, Krasnoarmeyskaya str., 72
A. V. Rylov
Kirov Research Institute of Hematology and Blood Transfusion of FMBA of Russia
Russian Federation
Russian Federation
doctor of medical sciences
6100027, Kirov, Krasnoarmeyskaya str., 72
References
1. Valiev T.T., Kovrigina A.M., Popa A.V., Levashov A.S., Mentkevich G.L. Modern possibilities of diagnostics and treatment of diffuse large b-cell lymphoma in children and adults (literature review). Sovremennaya onkologiya = Journal of Modern Oncology. 2015; (3): 30–41. [In Russian].
2. Dyakonov D.A, Rosin V.A., Vaneeva E.V., Samarina S.V. A method of morphometric assessment of the prognosis of diffuse B-large cell lymphoma by the content of STAT3 tumor cells in lymph nodes. Patent 2694838 RF; Published 17.07. 2019. [In Russian].
3. Poddubnaya I.V. Diffuse large B-cell lymphoma. In: Russian clinical recommendations on diagnostics and treatment of lymphoproliferative disorders. Eds. I.V. Poddubnaya, V.G. Savchenko. Moscow: Buki Vedi, 2018. 58–65. [In Russian].
4. Rastorguev S.M., Koroleva D.A., Bulygina E.S., Tsygankova S.V., Goncharov N.G., Naraykin O.S., Gabeeva N.G., Zvonkov E.E., Nedoluzhko A.V. Clinical and prognostic value of molecular markers of diffuse large B-cell lymphoma. Klinicheskaya onkogematologiya = Clinical Oncohematology. 2019; 12 (1): 95–100. [In Russian]. doi: 10.21320/2500-2139-2019-12-1-95-100.
5. Shaposhnikov A.V., Komar’kov I.F., Lebedeva L.A., Shidlovskii Yu.V. Molecular components of JAK/STAT signaling pathway and its interaction with transcription machinery. Mol. Biol. 2013; 47 (3): 343–351. doi: 10.7868/s0026898413030130.
6. Aaronson D.S., Horvath C.M. A road map for those who don’t know JAK-STAT. Science. 2002; 296 (5573): 1653–1655. doi: 10.1126/science.1071545.
7. Adida C., Haioun C., Gaulard P., Lepage E., Morel P., Briere J., Dombret H., Reyes F., Diebold J., Gisselbrecht C., Salles G., Altieri D.C., Molina T.J. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood. 2000; 96 (5): 1921–1925.
8. Alizadeh A.A., Eisen M.B., Davis R.E. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000. 403: 503–511. doi: 10.1038/35000501.
9. Bastion Y., Blay J.Y., Divine M., Brice P., Bordessoule D., Sebban C., Blanc M., Tilly H., Lederlin P., Deconinck E., Salles B., Dumontet C., Briere J., Coiffier B. Elderly patients with aggressive non-Hodgkin’s lymphoma: disease presentation, response to treatment, and survival – a Groupe d’Etude des Lymphomes de l’Adulte study on 453 patients older than 69 years. J. Clin. Oncol. 1997; 15 (8): 2945–2953. doi: 10.1200/JCO.1997.15.8.2945.
10. Сabattini E., Pileri S.A., Dirnhofer S., Went P., Ascani S., Marafioti T., Tzankov A., Leoncini L., Falini B., Zinzani P.L. Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification. Histopathology. 2002; 41 (6): 482–509. doi: 10.1046/j.1365-2559.2002.01538.x.
11. Darnell J.E. Validating Stat3 in cancer therapy. Nat. Med. 2005; 11: 595–596. doi: 10.1038/nm0605-595.
12. Ding B.B., Yu J.J., Yu R.Y., Mendez L.M., Shaknovich R., Zhang Y., Cattoretti G., Ye B.H. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood. 2008; 111 (3): 1515–1523. doi: 10.1182/blood-2007-04-08773.doi: 10.1182/blood-2007-04-087734.
13. Gomez H., Mas L., Casanova L., Pen D.L., Santillana S., Valdivia S., Otero J., Rodriguez W., Carracedo C., Vallejos C. Elderly patients with aggressive non-Hodgkin’s lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. J. Clin. Oncol. 1998; 16 (7): 2352–2358. doi: 10.1200/JCO.1998.16.7.2352.
14. Hans C.P., Weisenburger D.D., Greiner T.C., Gascoyne R.D., Delabie J., Ott G., Muller Hermelink H.K., Campo E., Braziel R.M., Jaffe E.S., Pan Z., Farinha P., Smith L.M., Falini B., Banham A.H., Rosenwald A., Staudt L.M., Connors J.M., Armitage J.O., Chan W.C. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103 (1): 275–282. doi: 10.1182/blood-2003-05-1545.
15. Huang X., Meng B., Iqbal J., Ding B.B., Perry A.M., Cao W., Smith L.M., Bi C., Jiang C., Greiner T.C., Weisenburger D.D., Rimsza L., Rosenwald A., Ott G., Delabie J., Campo E., Braziel R.M., Gascoyne R.D., Cook J.R., Tubbs R.R., Jaffe E.S., Armitage J.O., Vose J.M., Staudt L.M., McKeithan T.W., Chan W.C., Ye B.H., Fu K. Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP. J. Clin. Oncol. 2013; 31 (36): 4520-4528. doi: 10.1200/JCO.2012.45.6004
16. Lam L.T., Wright G., Davis R.E. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma. Blood. 2008; 111: 3701–3713. doi: 10.1182/blood-2007-09-111948.
17. Lin S., Yujun L., Xiaoming X., Wenwen R. Expression and significance of leptin receptor, p-STAT3 and p-AKT in diffuse large B-cell lymphoma. Acta Histochem. 2014; 116: 126–130. doi: 10.1016/j.acthis.2013.06.003.
18. Liu H., Zhu L., Sun C., Xie W., Qian W., Ye X. Clinical significance and prognostic value of STAT3 expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. Int. J. Clin. Exp. Med. 2016; 9 (6): 9356–9364.
19. Meyer P.N., Fu K., Greiner T.C., Smith L.M., Delabie J., Gascoyne R.D., Ott G., Rosenwald A., Braziel R.M., Campo E., Vose J.M., Lenz G., Staudt L.M., Chan W.C., Weisenburger D.D. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J. Clin. Oncol. 2011; 29 (2): 200–207. doi: 10.1200/JCO.2010.30.0368.
20. Morgensztern D., Lossos I.S. Molecular prognostic factors in diffuse large B-cell lymphoma. Curr. Treat. Options Oncol. 2005; 6 (4): 269–277.
21. Ok C.Y., Chen J., Xu-Monette Z.Y., Tzankov A., Manyam G.C., Li L., Visco C., Montes-Moreno S., Dybkaer K., Chiu A., Orazi A., Zu Y., Bhagat G., Richards K.L., Hsi E.D., Choi W.W., van Krieken J.H., Huh J., Zhao X., Ponzoni M., Ferreri A.J., Bertoni F., Farnen J.P., Moller M.B., Piris M.A., Winter J.N., Medeiros L.J., Young K.H. Clinical implications of phosphorylated STAT3 expression in de novo diffuse large B-cell lymphoma. Clin. Cancer Res. 2014; 20 (19): 5113–5123. doi: 10.1158/1078-0432.CCR-14-0683.
22. Ok C.Y., Chen J., Xu-Monette Z.Y., Tzankov A., Visco C., Chiu A., Orazi A., Zu Y., Bhagat G., Richards K.L., Hsi E.D., Choi W.W., van Krieken J.H., Ponzoni M., Ferreri A.J., Farnen J.P., Moller M.B., Winter J.N., Piris M.A., Medeiros L.J., Young K.H. STAT3 expressions and clinical inplications in de Novo diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013; 122: 365.
23. Rawlings J.S., Rosler K.M., Harrison D.A. The JAK/STAT signaling pathway. J. Cell Sci. 2004; 117 (8): 1281–1283. doi: 10.1242/jcs.00963.
24. Rosenwald A., Wright G., Chan W.C. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 2002; 346 (25): 1937–1947. doi: 10.1056/NEJMoa012914.
25. Sehn L.H., Gascoyn R.D. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015; 125 (1): 22–32. doi: 10.1182/blood-2014-05-577189.
26. Shipp M.A., Ross K.N., Tamayo P. Diffuse large B-cell lymphoma outcome prediction by geneexpression profiling and supervised machine learning. Nat. Med. 2002; 8: 68–74. doi: 10.1038/nm0102-68.
27. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th Edition. Eds. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele. Geneva: WHO Press, 2017. 585 p.
28. Wu Z.L., Song Y.Q., Shi Y.F., Zhu J. High nuclear expressions of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma. J. Hematol. Oncol. 2011; 4 (31): 1–6. doi: 10.1186/1756-8722-4-31.
29. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer. 2009; 9 (11): 798–809. doi: 10.1038/nrc2734.
Review
Views:
351
Email this article 